Compare iShares MSCI Hong Kong ETF (EWH) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI Hong Kong ETF trades at $22.46, while Novo Nordisk A/S trades at $46.39 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals.
| EWH | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $63.98 |
52-Week Low | $20.66 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH trades at $22.45, down 1.54% on the day, with a bearish technical signal from moving averages and neutral oscillators. Recent news highlights the Hang Seng Index's rebound and potential golden cross formation, driven by technology stock recoveries. The ETF shows no available fundamental ratios in the provided data, but tracks Hong Kong equities, with a dividend scheduled for June 2026.
Outlook hinges on Hong Kong market performance and tech sector momentum. Risks include Asian market volatility and geopolitical factors. Analyst sentiment is mixed, with some bullish on Hong Kong over Korea, while technicals suggest caution near support at $22.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
